Summary of clinical trials comparing liberal vs restrictive transfusion strategies
| Outcome . | Trials . | N . | Restrictive, n/N (%) . | Liberal, n/N (%) . | Relative risk (95% CI) . |
|---|---|---|---|---|---|
| 30-d mortality | 31 | 16 729 | 670/8321 (8.1) | 689/8408 (8.2) | 0.99 (0.86-1.15) |
| Myocardial infarction | 23 | 14 370 | 237/7205 (3.3) | 229/7165 (3.2) | 1.04 (0.87-1.24) |
| CHF | 16 | 7 247 | 100/3642 (2.7) | 126/3605 (3.5) | 0.83 (0.53-1.29) |
| Infection | 25 | 17 104 | 1143/8492 (13.5) | 1230/8612 (14.3) | 0.97 (0.88-1.07) |
| Thromboembolism | 13 | 4 201 | 35/2102 (1.7) | 32/2099 (1.5) | 1.11 (0.65-1.88) |
| Rebleeding | 8 | 3 412 | 231/1641 (14.1) | 279/1771 (15.8) | 0.80 (0.59-1.09) |
| Blood transfusion | 42 | 20 057 | 4971/9997 (49.7) | 8203/10060 (81.5) | 0.59 (0.53-0.66) |
| Outcome . | Trials . | N . | Restrictive, n/N (%) . | Liberal, n/N (%) . | Relative risk (95% CI) . |
|---|---|---|---|---|---|
| 30-d mortality | 31 | 16 729 | 670/8321 (8.1) | 689/8408 (8.2) | 0.99 (0.86-1.15) |
| Myocardial infarction | 23 | 14 370 | 237/7205 (3.3) | 229/7165 (3.2) | 1.04 (0.87-1.24) |
| CHF | 16 | 7 247 | 100/3642 (2.7) | 126/3605 (3.5) | 0.83 (0.53-1.29) |
| Infection | 25 | 17 104 | 1143/8492 (13.5) | 1230/8612 (14.3) | 0.97 (0.88-1.07) |
| Thromboembolism | 13 | 4 201 | 35/2102 (1.7) | 32/2099 (1.5) | 1.11 (0.65-1.88) |
| Rebleeding | 8 | 3 412 | 231/1641 (14.1) | 279/1771 (15.8) | 0.80 (0.59-1.09) |
| Blood transfusion | 42 | 20 057 | 4971/9997 (49.7) | 8203/10060 (81.5) | 0.59 (0.53-0.66) |